The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer
Open Access
- 18 February 2022
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 13 (1) , 393-407
Abstract
Https://doi.org/10.18632/oncotarget.28202 Alexander W. Pohlman, Hita Moudgalya, Lia Jordano, Gabriela C. Lobato, David Gerard, Michael J. Liptay, Christopher W. Seder, Jeffrey A. BorgiaKeywords
All Related Versions
This publication has 90 references indexed in Scilit:
- Expression and clinical significance of IGF-1, IGFBP-3, and IGFBP-7 in serum and lung cancer tissues from patients with non-small cell lung cancerOncoTargets and Therapy, 2013
- Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor SurvivalPLOS ONE, 2013
- IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutationsScientific Reports, 2013
- Association between Circulating Levels of IGF-1 and IGFBP-3 and Lung Cancer Risk: A Meta-AnalysisPLOS ONE, 2012
- Autoantibodies against insulin-like growth factor-binding protein-2 as a serological biomarker in the diagnosis of lung cancerInternational Journal of Oncology, 2012
- The Insulin-Like Growth Factor System in CancerEndocrinology and Metabolism Clinics of North America, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Combined inhibition of insulin-like growth factor-1 receptor enhances the effects of gefitinib in a human non-small cell lung cancer resistant cell lineExperimental and Therapeutic Medicine, 2011
- Differences between Human Plasma and Serum Metabolite ProfilesPLOS ONE, 2011
- Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studiesThe Lancet Oncology, 2010